Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q2 FY26 Earnings Presentation
34 slides from Supriya Lifescience's earnings presentation, Nov 12, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
SUPRIYA LIFESCIENCE LTD. .. e Creating true va lues that bind global lzealtl, November 12, 2025 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 S
Slide 2: Investor Presentation | Q2 FY26
SUPRIYA LIFESCIENCE LTD. SUPRIYA LIFESCIENCE LTD. Investor Presentation | Q2 FY26
Slide 3: Safe Harbour
Safe Harbour SUPRIYA LIFESCIENCE LTD. This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purch
Slide 4: Q2 FY26 Highlights
Q2 FY26 Highlights SUPRIYA LIFESCIENCE LTD.
Slide 5: Q2 FY26 Highlights: Regional Performance
Q2 FY26 Highlights SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT Quarterly INR 1,998.3 Mn INR 726.5 Mn INR 683.2 Mn INR 504.3 Mn 20% YoY 12% YoY 10% YoY 9% YoY Business Mix Revenue Contribution – By Region Regional Performance 41% 38% 37% 32% 32% 34% ■ Q2 FY25 19% 17% 21% ■ Q1 FY26 6% 6% ■ Q2 FY26
Slide 6: H1 FY26 Highlights: Regional Performance
H1 FY26 Highlights SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT Quarterly INR 3,449.1 Mn INR 1,243.5 Mn INR 1,157.3 Mn INR 852.2 Mn 6% YoY 2% YoY 5% YoY 6% YoY Business Mix Revenue Contribution – By Region Regional Performance 39% 36% 36% 33% ■ H1 FY25 20% 19% ■ H1 FY26 4% 4% 4% 5% Asia Europe LA
Slide 7: Q2 & H1 FY26 - Y-o-Y Highlights
~ SUPRIYA Q2 & H1 FY26 - Y-o-Y Highlights ~ LIFESCIENCE LTD. (in INR Mn) Revenue EBITDA PBT PAT 20% YoY 6% YoY 12% YoY 2% YoY 10% YoY 5% YoY 9% YoY 6% YoY 3449.1 1272.6 1243.6 907.9 852.2 3267.3 1218.4 1157.3 1998.3 726.6 683.2 461.5 504.3 1661.0 647.2 620.6 .J_ Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2
Slide 8: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy SUPRIYA LIFESCIENCE LTD. Performance of the Top Therapeutic Areas 54% 46% 12% 11% 12% 10% 8% 6% 7% 5% 4% - • -- 2% 3% 2% Anesthetic Analgesic Anti-Histamine Vitamins Anti-Asthmatic Anti-Allergic Anti-hypertensive ■ H1 FY25 ■ H1 FY26 7
Slide 9: Profit & Loss Statement
Profit & Loss Statement SUPRIYA LIFESCIENCE LTD. Particulars (in INR Mn) Q2 FY26 Q2 FY25 Y-o-Y Q1 FY26 Q-o-Q H1 FY26 H1 FY25 Y-o-Y Revenue from Operations 1,998.3 1,661.0 20.3% 1,450.7 37.7% 3,449.1 3,267.3 5.6% ,- ,- ,- Cost of Goods Sold 557.3 459.8 21.2% 317.7 75.4% 875.0 945.7 -7.5% +- +- +- +-
Slide 10: Balance Sheet
Balance Sheet SUPRIYA LIFESCIENCE LTD. Assets Mar 25 Sep 25 Equity and Liabilities Mar 25 Sep 25 Non-current assets Equity (i) Property, plant and equipment 4,468 4,519 (i) Equity share capital 161 161 (ii) Right to Use Asset 46 44 (ii) Other equity 9,807 10,657 (iii)Capital Work in progress 1,480 1
Slide 11: Company Overview
Company Overview SUPRIYA LIFESCIENCE LTD.
Slide 12: Business Overview
Business Overview SUPRIYA LIFESCIENCE LTD. Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics 40+ APIs 120+ Countries 35,000 Sq.mts 932 KLPD Niche product basket Diversified operations with presence Manufacturing facility spread across Reactor capacity WHO-GMP,
Slide 13: Journey So Far
Journey So Far SUPRIYA LIFESCIENCE LTD. 2020 • Third time -.-2021 • CEP granted for Pentoxifylline, Esketamine -.-2022 • CEP (Certificate of 2023 • The Company commenced -.- 2024 • ANVISA Approval USFDA approval Hydrochloride and Salbutamol Sulphate; suitability ) renewed for operations at its Grant
Slide 14: Backward Integrated Business Model
Backward Integrated Business Model SUPRIYA LIFESCIENCE LTD. + + Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of essential raw Protection against market Less Dependence On External Increasing margins materials fluctuations Parties 18 products are backward
Slide 15: Diversified Geographic Presence
~ SUPRIYA Diversified Geographic Presence ~ LIFESCIENCE LTD. ~ ... _.. ·.£ ~ -:,'! ,II! I . Launches New Therapies • Contrast Media • Cardio Vascular • ADHD New Products Launched new product to further strengthen the Anesthetic therapy Presence in 120+ portfolio Countries Across Globe 14
Slide 16: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence SUPRIYA LIFESCIENCE LTD. Significant export presence, with low dependence on a … with balanced customer concentration specific geography Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 85
Slide 17: Advanced Manufacturing
~ SUPRIYA Advanced Manufacturing ~ LIFESCIENCE LTD. o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, i 55 9 warehouse, raw materials, packaging materials and I I Manufacturing Blocks Clean Rooms I finished goods s
Slide 18: R&D Capabilities
R&D Capabilities SUPRIYA LIFESCIENCE LTD. Supported by R&D driven mindset DSIR approved facility • A team of 60+ scientists primarily focused on API process development across the value chain • Already started two R&D centres – 4* Process Patent o Ambernath R&D – Formulations and Generic APIs Filed
Slide 19: CMO Capabilities
CMO Capabilities SUPRIYA LIFESCIENCE LTD. • State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation • Complete support in validation, stability, & compilation of dossiers • Dedicated technology transfer team is periodically
Slide 20: Recently Commissioned state-of-the-art E Block
Recently Commissioned state-of-the-art E Block SUPRIYA LIFESCIENCE LTD. • Capacity: 335 KLPD • Large volume equipment – multipurpose synthesis with focus on backward integration capabilities • Closed systems using gravity flow equipped with process control system. 19
Slide 21: FDF Facility ready for commissioning at Ambernath
FDF Facility ready for commissioning at Ambernath SUPRIYA LIFESCIENCE LTD. • The site spans 5,000 sqm, with 70% of the area constructed, Facility located at Plot No. N-60, Additional Ambernath MIDC, District Location Thane, Maharashtra, • Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km f
Slide 22: Complex Chemistries & Reaction (1/2)
Complex Chemistries & Reaction (1/2) SUPRIYA LIFESCIENCE LTD. Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. High vacuum distillations • Cyclisation Grignard reaction Simple to
Slide 23: Complex Chemistries & Reaction (2/2)
Complex Chemistries & Reaction (2/2) SUPRIYA LIFESCIENCE LTD. Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. Chiral molecules synthesis using Chiral auxiliary • Contrast media
Slide 24: Regulatory Achievements
Regulatory Achievements SUPRIYA LIFESCIENCE LTD. Strong focus on compliance guided by ethical approach • Our motto is to consistently meet the stringent requirements of regulatory bodies • Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and ma
Slide 25: Awards & Accreditation
Awards & Accreditation SUPRIYA LIFESCIENCE LTD . 2016 2017 2019 • Export House for the Year for 2015-16 awarded by • Export House for the Year for 2016-17 awarded by • Outstanding Export Performance Award for the year Directorate of Directorate of Industries, Government of Maharashtra 2018-19 for pr
Slide 26: Key Management Team
Key Management Team SUPRIYA LIFESCIENCE LTD. Satish Wagh Executive Chairman & WTD • An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University. • B.Sc. from R.D National College and W.A. Science College, University of Bombay. • Director on the board of Sup
Slide 27: EHS
EHS SUPRIYA LIFESCIENCE LTD. Environment Health Safety • Regular and strict monitoring to produce highest • Clean, safe and healthy working environment for our • Committed to safe and accident-free operations in all efficiency in pollution control all employees our establishments • Safeguarding our
Slide 28: CSR & Social Work
CSR & Social Work SUPRIYA LIFESCIENCE LTD. We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm • Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from t
Slide 29: Historical Financial Performance
Historical Financial Performance SUPRIYA LIFESCIENCE LTD.
Slide 30: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance SUPRIYA LIFESCIENCE LTD. (in INR Mn) Robust revenue growth Capex Spend … and, focus on profitability 15.5% 1,623 2,608 1,457 2,140 6,965 1,732 1,880 1,880 949 1,078 1,518 5,301 5,703 1,236 1,289 1,191 3,912 4,609 899 FY21 FY22 FY23 FY24 FY25 --- FY21 94 FY22
Slide 31: Working Capital Break-up
Working Capital Break-up SUPRIYA LIFESCIENCE LTD. Inventory Receivables 233 73 206 71 72 198 172 165 63 61 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Payables Net Working Capital 113 112 235 194 196 75 158 59 124 49 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 30
Slide 32: Future Outlook
Future Outlook SUPRIYA LIFESCIENCE LTD.
Slide 33: Future Outlook
Future Outlook SUPRIYA LIFESCIENCE LTD. Two new R&D centres CMO/CDMO space • The future of the company is deeply rooted in R&D, with significant progress made to • Company understands large scale special chemical manufacturing and has experience in enhance research capabilities handling hazardous co
Slide 34: Thank You
e SUPRIYA LIFESCIENCE LTD. Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com EV Ernst & Young LLP Runjhun Jain Sneha Salian +91 98207 20993 +91 98194 30437 runjhun.jain1@in.ey.com sneha2.sali